VKTX · CIK 1607678
What Viking Therapeutics, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for VKTX. More may follow as additional filings are processed.
In its own words
What could break it.
Supplier concentration
- limited raw-material suppliers; reliance on third-party manufacturersmedium
Viking has no internal manufacturing and relies on third-party CMs (e.g., CordenPharma for VK2735); a limited number of suppliers exist for the raw materials needed, risking disruption of clinical/commercial supply.
“There are a limited number of suppliers for raw materials that we use to manufacture our drugs, and there may be a need to identify alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our drug candidates for our clinical trials, and, if approved, ultimately for commercial sale.”
SEC filing →As of 2026
Regulatory & policy
- U.S. drug-pricing reform (IRA, ACA, Medicare cuts)low
Healthcare reform — the IRA, ACA and ongoing Medicare funding reductions — and state importation/price-control measures could lower future pricing and reimbursement for any approved Viking products.
“We expect that the ACA, the IRA, and any other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
CordenPharma Colorado, Inc.
“We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture our preclinical and clinical drug supplies for use in our clinical trials, and other than the agreements with Corden Pharma Colorado, Inc. and its affiliates, or CordenPharma, for VK2735, we lack the current resources and the capability to manufacture any of our drug candidates on a clinical or commercial scale.”
Cited →Ligand Pharmaceuticals Incorporated
“A summary of the Master License Agreement can be found under the heading “Master License Agreement with Ligand” under Part I, “Item 1. Business” of this Annual Report on Form 10-K.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch